A Phase 1/2 Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Bevacizumab for Adult Patients With Recurrent Malignant Glioma Post-Bevacizumab Failure

Trial Profile

A Phase 1/2 Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Bevacizumab for Adult Patients With Recurrent Malignant Glioma Post-Bevacizumab Failure

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2016

At a glance

  • Drugs Carboxyamidotriazole orotate (Primary) ; Bevacizumab
  • Indications Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Feb 2016 Status changed from suspended to discontinued, according to ClinicalTrials.gov record.
    • 02 Jun 2015 Interim results (n=15) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 18 May 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top